Effectiveness of the 10 cm² Rivastigmine Patch in Taiwanese Patients with Mild-to-Moderate Alzheimer's Dementia: A 48-Week Real-World Observational Study.

ABSTRACT:

Introduction

The current study aimed to provide data on the effectiveness of the 10 cm² rivastigmine patch in patients with Alzheimer's disease (AD) in a real-world setting in Taiwan.

Methods

This was a 48-week, single-arm, open-label, observational, and post-marketing study conducted across seven centers in Taiwan between May 5, 2016 and July 10, 2017. Eligible patients (aged 55-95 years) treated with the 10 cm²rivastigmine patch were enrolled based on physicians' judgment and according to the Taiwan reimbursement criteria of the drug. Data were prospectively collected at Week 0 (baseline), Week 24, and Week 48. The primary endpoint was the change in the cognitive assessment screening instrument (CASI) scores at Week 48 versus baseline. The changes fro

SUBMITTER: Chang CC 

PROVIDER: S-EPMC8478746 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature